Dogwood Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), Unrealized
Dogwood Therapeutics, Inc. (DWTX) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$36.43 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-14
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$30.57K, a 690.82% decline year-over-year.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$5.86K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$10.96K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$15.24K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$27.92K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$30.79K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$36.43K 10-Q · filed 2026-08-14 | -$47.39K derived: sum of 3 quarters · filed 2026-08-14 | -$62.63K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$5.86K 10-Q · filed 2026-05-15 | -$16.82K derived: sum of 2 quarters · filed 2026-05-15 | -$32.06K derived: sum of 3 quarters · filed 2026-05-15 | -$26.89K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$10.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$26.20K derived: sum of 2 quarters · filed 2026-03-18 | -$21.03K derived: sum of 3 quarters · filed 2026-08-14 | -$27.92K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$15.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$10.07K derived: sum of 2 quarters · filed 2026-08-14 | -$16.95K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $5.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.71K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -$6.89K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$30.79K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |